H.C. Wainwright has recently reduced Bioatla Inc (BCAB) stock to Neutral rating, as announced on November 13, 2024, according to Finviz. Earlier, on September 15, 2022, JMP Securities had initiated the stock to Mkt Outperform, setting a price target of $17. Credit Suisse also reduced Neutral rating with a price target of $5. Additionally, H.C. Wainwright initiated Buy rating on March 21, 2022, with a target price of $25. BTIG Research analysts, in their report published on October 15, 2021, also resumed Buy rating for Bioatla Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Bioatla Inc (BCAB) Stock Trading Recap
On Monday, Bioatla Inc (BCAB) stock saw a decline, ending the day at $0.38 which represents a decrease of $-0.07 or -15.56% from the prior close of $0.45. The stock opened at $0.44 and touched a low of $0.38 during the day, reaching a high of $0.47. The volume of shares traded was 1.74 million exceeding the average volume of 1.10 million.
Sponsored
BCAB Stock Performance and Moving Averages
In recent trading, Bioatla Inc (BCAB) stock price has shown some volatility, fluctuating -15.37% over the last five trades and -31.38% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -73.86%, and it has plunged by -81.34% in the previous three months. Currently, BCAB is trading at -19.84%, -55.51%, and -76.38% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, BCAB, a Healthcare sector stock, is trading -90.44% below its 52-week high but remains -9.58% above its 52-week low. The Average True Range (ATR) (14 days) of 0.06 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Bioatla Inc’s Profitability and Valuation Ratios
Bioatla Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -783.95% and a profit margin of -743.79%, with a gross margin of -73.86%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Bioatla Inc’s market capitalization stands at $22.30 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 2.03, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 0.81, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.07% of Bioatla Inc (BCAB)’s shares, while financial institutions hold 24.62%.
